Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets

Journal of Pharmaceutical Sciences

Volumn 92, Issue 3, 2003, Pages 604-610

  Siegmund, Werner ^a   Ludwig, Karen ^a   Engel, Georg ^a   Zschiesche, Michael ^a   Franke, Gerd ^a   Hoffmann, Anna ^a,b   Terhaag, Bernd ^a,b   Weitschies, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Arzneimittelwerk Dresden GmbH   (Germany)

Author keywords

Bioavailability; P glycoprotein; Talinolol

Indexed keywords

GLYCOPROTEIN P; TALINOLOL;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE; TABLET;

EID: 0037373359     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10327     Document Type: Article

References (35)

1. Schmidt J. 1995. Talinolol, ein klinisch bewährter β1-selektiver Betablocker - Eine Übersicht zu pharmakokinetischen und pharmakodynamischen Eigenschaften. Perfusion 8:291-296.
2. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. 2000. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355.
3. Gramatté T, Oertel R, Terhaag B, Kirch W. 1996. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans. Clin Pharmacol Ther 59:541-549.
4. Giessmann T, Zschiesche M, Modess C, Tschuschke A, Hartmann V, Weitschies W, Siegmund W. 2001. Is the double peak phenomenon of talinolol caused by lymphatic transport? Pharmacol Toxicol 89(Suppl I):73.
5. Westphal K, Weinbrenner A, Gießmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. 2000. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12.
6. Trausch B, Oertel R, Richter K, Gramatté T. 1995. Disposition and bioavailability of the β1-adrenoceptor antagonist talinolol in man. Biopharm Drug Disp 16:403-414.
7. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P. 1996. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514-522.
8. Gramatté T, Oertel R. 1999. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66:239-245.
9. Suzuki H, Sugiyama Y. 2000. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
10. Junginger H. 1987. Studies on bioavailability and bioequivalence. Drugs made in Germany 30:161-166.
11. Committee for proprietary medicinal products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/1401/98.
12. Sauter R, Steinijans VW, Diletti E, Böhm A, Schultz HU. 1992. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30(Suppl 1):7-30.
13. Steinijans VW, Hauschke D. 1993. International harmonisation of regulatory bioequivalence requirements. Clin Res Regul Aff 10:203-220.
14. Steinijans VW, Sauter R, Hauschke D, Elze M. 1995. Metrics to characterize concentration time profiles in single- and multiple-dose bioequivalence studies. Drug Inf J 29:981-987.
15. Hauschke D, Steinijans VW, Diletti E, Schall R, Luus HG, Elze M, Blume H. 1994. Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies. Int J Clin Pharmacol Ther 32:376-378.
16. Schwarz UI, Gramatté T, Krappweis J, Oertel R, Kirch W. 2000. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161-167.
17. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance geene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
18. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. 1987. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269.
19. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. 1996. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br J Pharmacol 118:1841-1847.
20. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. 1997. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:11552-1562.
21. Zhang Y, Benet LZ. 2001. The gut as a barrier to drug absorption. Combined role of cytochrome P4503A and P-glycoprotein. Clin Pharmacokinet 40:159-168.
22. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. 1999. Effects of rifampin on tracrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39:91-96.
23. Lown KS, Mayo RR, Leichtman AB, Hsiao H, Turgeon K, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
24. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. 1999. The interaction of digoxin and rifampin: Role of intestinal P-glycoprotein. J Clin Invest 104:147-153.
25. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66:338-345.
26. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. 2000. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
27. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. 1999. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 66:391-400.
28. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmüller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphism of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
29. Altmannsberger S, Paneitz A, Franke G, Knoke M, Sperker B, Terhaag B, Meng W, Warzok R, Schroeder E, Weibrenner A, Zschiesche M, Cascorbi I, Kroemer HK, Siegmund W. 2000. Chronic thyroxine induces intestinal P-glycoprotein and elimination of talinolol in healthy volunteers. Eur J Clin Pharmacol Suppl 56:A16.
30. Döppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H. 1999. Characterization of binding properties to human P-glycoprotein: Development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther 288:348-357.
31. Döppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. 1999. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 88:1067-1072.
32. Tannergren C, Langguth P, Hoffmann KJ. 2001. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie 56:337-342.
33. Spahn-Langguth H, Langguth P. 2001. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367.
34. Hanafy A, Langguth P, Spahn-Langguth H. 2001. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur J Pharm Sci 12:405-415.
35. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I. 2002. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572-583.